in one analyst report months ago. there was some physcians that were interviewed that did not even know about Ponatinib yet.
i dont have much faith in these interviews at all.
A US survey on ARIAD Pharmaceuticals' (NASDAQ: ARIA) Iclusig suggests some risk to launch, said Oppenheimer. Following the drug's approval by the FDA, which included a box warning arterial thrombosis and liver toxicity, analyst conducted a physician survey.
"The results do not diminish our confidence in Iclusig's significant long-term market opportunity. However, the survey revealed some increased physician caution around Iclusig's side effects and initial adoption,” said analyst David Ferreiro, Ph.D.
"The large majority of surveyed physicians maintained a strong view of Iclusig's profile, despite Iclusig's boxed warning. However, there appears to have emerged a 15% minority of physicians who find Iclusig's arterial thrombosis and liver toxicity to be prohibitive,” said Ferreiro.
Oppenheimer has a Perform rating on ARIAD Pharmaceuticals with a price target of $23.00.
News 
Market Data 
Discover 
